Pons metabolite alterations in narcolepsy type 1
- PMID: 39951174
- PMCID: PMC11920375
- DOI: 10.1007/s10072-025-08009-w
Pons metabolite alterations in narcolepsy type 1
Abstract
Introduction: Narcolepsy type 1 (NT1) is a rare central sleep disorder characterized by a selective loss of hypocretin/orexin (hcrt)-producing neurons in the postero-lateral hypothalamus that project to widespread areas of the brain and brainstem. The aim of this study was to explore in a group of NT1 patients the metabolic alterations in the pons and their associations with disease features.
Methods: Twenty-one NT1 patients (16 M) and twenty age-matched healthy controls (10 M) underwent a brain 1H MRS on a 1.5 T GE Medical Systems scanner. Metabolite content of N-acetyl-aspartate (NAA), choline (Cho), and myo-inositol (mI) were estimated relative to creatine (Cr), using LCModel 6.3. Clinical data were also collected with validated questionnaires, polysomnography, the Multiple Sleep Latency Test (MSLT), Cerebrospinal fluid hypocretin-1 (CSF hcrt-1) concentration and genetic markers.
Results: NT1 patients compared with healthy controls showed lower NAA/Cr ratio (p = 0.007) and NAA/mI ratio (p = 0.011) in the pons. The Epworth Sleepiness Scale score showed a significant negative correlation with NAA/Cr content (p = 0.023), MSLT sleep latency a negative correlation with the mI/Cr ratio (p = 0.008), and sleep onset REM periods a positive correlation with the mI/Cr ratio (p = 0.027). CSF hcrt-1 levels were positively correlated with the NAA/Cr ratio (p = 0.039) and negatively with the mI/Cr ratio (p = 0.045) and the Cho/Cr ratio (p = 0.026).
Conclusion: The metabolic alterations found in the pons of NT1 patients using the MR Spectroscopy technique were associated with subjective and objective disease severity measures, highlighting the crucial role of this biomarker in the pathophysiology of the disease.
Keywords: Metabolic alterations; Narcolepsy type 1; Pons; Proton MR spectroscopy.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethical approval: The study protocol was approved by the local AVEC Ethics Committee (17009-EM1-OSS-AUSLBO − 17009) and informed written consent was obtained from all participants. Conflict of interest: The authors have no conflict of interest to declare.
Figures

References
-
- Plazzi G, Montagna P, Provini F, Bizzi A, Cohen M, Lugaresi E (1996) Pontine lesions in idiopathic narcolepsy. Neurology 46(5):1250–1250. 10.1212/wnl.46.5.1250 - PubMed
-
- Ellis CM, Simmons A, Lemmens G, Williams SCR, Parkes JD (1998) Proton spectroscopy in the narcoleptic syndrome: is there evidence of a brainstem lesion? Neurology 50(2suppl1):S23–S26. 10.1212/wnl.50.2_suppl_1.s23 - PubMed
-
- Bican A, Bora I, Algin O, Hakyemez B, Ozkol V, Alper E (2009) Neuroimaging in narcolepsy. Sleep Med 11(2):225–226. 10.1016/j.sleep.2009.05.011 - PubMed
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources